Review Article
A New Hope in Immunotherapy for Malignant Gliomas: Adoptive T Cell Transfer Therapy
Table 2
Comparison of the effector cells used in adoptive T cell therapy for malignant glioma.
| Effector cells | Advantages | Disadvantages |
| Lymphokine-activated killer (LAK) cells | MHC-independent cytotoxicity Easy preparation of cells | Nonspecific killing IL-2 related toxicities |
| Natural killer (NK) cells | MHC-independent cytotoxicity Immediate response Can be modified to target tumor antigens genetically | Nonspecific killing |
| γ δ T cells | MHC-independent cytotoxicity Immediate response | Nonspecific killing |
| Tumor infiltrating lymphocytes (TILs) | Presumably tumor-specific killing | Need T cells from tumor tissue Technical difficulty to expand ex vivo |
| CD4+ cytotoxic T lymphocytes | Tumor-specific killing | MHC class II-dependent cytotoxicity |
| CD8+ cytotoxic T lymphocytes | Tumor-specific killing Can be modified to target tumor antigens genetically | MHC class I-dependent cytotoxicity |
| Genetically modified cytotoxic T lymphocytes | MHC-independent cytotoxicity Rapid and elaborate tumor-specific killing | Induction of antigen loss variants at tumor recurrence Possible overreactivity on same target antigens expressed in normal tissue |
|
|